Carl Zeiss Meditec acquires two manufacturers of surgical instruments

Carl Zeiss Meditec announced today the acquisition of two manufacturers of surgical instruments (Kogent Surgical, LLC and Katalyst Surgical, LLC) to further strengthen its positioning as a solution provider.

Jena, Germany | 19 April 2022 | Carl Zeiss Meditec AG

Kogent Surgical and Katalyst Surgical are based in Chesterfield, Missouri (USA) and were founded by entrepreneur Gregg Scheller. Carl Zeiss Meditec AG President and CEO Dr. Markus Weber states: "This is a strategically important acquisition for ZEISS Medical Technology. We expect this acquisition to scale the businesses and contribute to our surgical solution offering and add recurring revenue." Gregg Scheller comments: "We already have a successful, long-term partnership with ZEISS and FCI (France Chirurgie Instrumentation S.A.S.) and we look forward to jointly expanding our solutions into other ZEISS applications and customer specialties." Financial terms of the deal are not disclosed.

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,531 employees worldwide, the Group generated revenue of €1,646.8m in fiscal year 2020/21 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Further Articles

Carl Zeiss Meditec achieves further significant growth in revenue and order intake in first half 2021/22

Strained supply chain situation in equipment business continues

Carl Zeiss Meditec generated revenue of €855.4m in the first six months of fiscal year 2021/22 (prior year: €767.4m),...

May 13, 2022

ZEISS Announces U.S. FDA Clearance of the QUATERA 700

ZEISS Announces U.S. FDA Clearance of the QUATERA 700. The latest technology from ZEISS empowers surgeons with one co...

Apr 20, 2022

ZEISS Innovation Day

ZEISS to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software App...

Apr 6, 2022